The International Neuromodulation SocietyThe Fastest-Growing, Worldwide Multidisciplinary Body Devoted to Building Knowledge of NeuromodulationThe International Neuromodulation Society (INS) is a non-profit group of clinicians, scientists and engineers dedicated to the scientific development and awareness of neuromodulation – the alteration of nerve activity through targeted delivery of a stimulus, such as electrical stimulation or chemical agents, to specific neurological sites in the body. The San Francisco-based INS was formed in 1989 and educates and promotes the field through meetings, its peer-reviewed journal Neuromodulation: Technology at the Neural Interface, mentorship, and chapter websites. The INS also provides information for patients and produces rolling news briefs about this rapidly evolving field. Donate TodayThe INS Peer-Reviewed JournalThe INS journal Neuromodulation: Technology at the Neural Interface has a growing Impact Factor and is indexed in Index Medicus, MEDLINE and Pubmed from its first issue in 1998. Members may log in to the members-only section to read the journal online. The journal also has social media accounts on Twitter, Facebook, and Instagram.
The Neuromodulation Podcast has been developed for our membership to dive into the forefront of today's emerging neuromodulation techniques, insights, and ethical and clinical applications. Join the multidisciplinary collaboration of medical care providers, scientists, and engineers who are part of the global conversation that's shaping the future of healthcare. Subscribe now wherever you get your podcasts. What is Neuromodulation?Medical Professionals can learn about various considerations concerning neuromodulation and clinic contacts. Once your preliminary questions have been answered, please use the Contact Us facility to find out more and to discuss specific objectives. Others may simply wish to join the INS and one of its related chapter societies, please use the Membership Application. Clinical trials that involve a wide range of emerging neuromodulation approaches are listed on our Research page. Neuromodulation clinical trials address symptom control through nerve stimulation in such condition categories as:
Breaking NewsDeep Brain Stimulation Provides Relief for Patient with Tourette Syndrome Patient March 7, 2026 - A woman with severe Tourette syndrome experienced substantial symptom improvement after undergoing deep brain stimulation. After the procedure and several months of recovery and device adjustment, her symptoms decreased significantly, allowing her to return to work, resume daily activities, and continue planning her future. The case highlights the potential of neuromodulation as a treatment option for patients with severe, treatment-resistant Tourette syndrome. (Source: MSN) Review Examines Clinical Trial Design Challenges for Transcutaneous Spinal Cord Stimulation March 6, 2026 - A methodological review analyzes challenges in designing rigorous clinical trials for transcutaneous spinal cord stimulation in chronic spinal cord injury, particularly difficulties in implementing effective sham controls. The authors highlight technical, ethical, and practical constraints, including participant burden and issues amplified by long study protocols and discuss alternative approaches such as sequential self-controlled, biomarker-guided, and adaptive trial designs. (Source: Nature) UC San Diego Review Maps Landscape of Vagus Nerve Modulation Therapies March 5, 2026 - A new review by researchers at the University of California San Diego synthesizes more than 660 studies examining how vagus nerve modulation therapies influence brain circuits, immune responses, and organ systems across a range of conditions. The authors report wide variation in devices, stimulation parameters, and study designs, which complicates comparisons and therapy optimization. They emphasize the need for greater standardization and suggest that future advances may include personalized stimulation guided by biomarkers, closed-loop systems, and artificial intelligence. (Source: National Today) Accelerated Brain Stimulation Shows Promise for Treatment-Resistant Depression January 16, 2025 - A noninvasive, accelerated brain stimulation therapy significantly reduced symptoms of treatment-resistant depression in a randomized controlled trial, with about half of treated participants achieving remission within one month. The approach uses personalized brain imaging to target stimulation and was associated with measurable changes in brain activity linked to mood regulation. Experts note that durability, accessibility, and effectiveness across more diverse populations require further study. (Source: CNN) FDA Approves First Physician-Directed At-Home Neuromodulation for Treatment-Resistant Depression January 12, 2026 - The U.S. Food and Drug Administration has approved a prescription, at-home brain neuromodulation therapy as an adjunctive treatment for adults with major depressive disorder who have not responded adequately to antidepressant medications. Approval via the PMA pathway was supported by a randomized, controlled multicenter trial, showing clinically meaningful benefit with a favorable safety profile. The decision expands access to evidence-based neuromodulation by allowing supervised treatment delivery beyond specialized clinic settings. (Source: PR Newswire) To see select neuromodulation news by category, as well as news about the INS in particular, please visit the Newsroom. To see archived news briefs dating back to January 2011, visit the News Archive. Continue Reading News Briefs |
